BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2021 8:04:00 AM | Browse: 336 | Download: 375
 |
Received |
|
2021-02-07 01:58 |
|
Peer-Review Started |
|
2021-02-07 02:02 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-06-17 03:39 |
|
Revised |
|
2021-06-27 10:20 |
|
Second Decision |
|
2021-08-30 03:29 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-08-30 07:16 |
|
Articles in Press |
|
2021-08-30 07:16 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-09-12 10:26 |
|
Typeset the Manuscript |
|
2021-10-21 04:07 |
|
Publish the Manuscript Online |
|
2021-10-26 08:04 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Minireviews |
| Article Title |
Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Lin-Lin Zheng, Chang-Cheng Tao, Zong-Gui Tao, Kai Zhang, An-Ke Wu, Jian-Xiong Wu and Wei-Qi Rong |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Beijing Hope Run Special Fund of Cancer Foundation of China |
LC2020L05 |
| CAMS Innovation Fund for Medical Science (CIFMS) |
CAMS-2016-I2M-3-025 |
|
| Corresponding Author |
Wei-Qi Rong, MD, Associate Professor, Surgeon, Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, No. 17 Panjiayuan South Lane, Beijing 100021, China. rongweiqi@sina.com |
| Key Words |
Programmed cell death 1/programmed cell death ligand 1 inhibitors; Targeted therapy; Hepatocellular carcinoma; Programmed cell death 1; Programmed cell death ligand 1 |
| Core Tip |
The incidence of liver cancer is high. Because the disease can develop rapidly, most patients progress to the intermediate or advanced stages and lose the opportunity to undergo radical hepatectomy. Targeted therapy brings a glimmer of hope for patients with advanced hepatocellular carcinoma. Immunotherapy is a major focus in the field of tumor therapy, and it represents a breakthrough in the treatment of advanced hepatocellular carcinoma. The combination of programmed cell death 1/programmed cell death ligand 1 inhibitors and targeted therapy, to potentially achieve the superposition of 1 + 1 > 2 effects, is a promising strategy for treating cancer. |
| Publish Date |
2021-10-26 08:04 |
| Citation |
Zheng LL, Tao CC, Tao ZG, Zhang K, Wu AK, Wu JX, Rong WQ. Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma . World J Gastrointest Surg 2021; 13(10): 1136-1148 |
| URL |
https://www.wjgnet.com/1948-9366/full/v13/i10/1136.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v13.i10.1136 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
